Free Trial

Compass Therapeutics (CMPX) Competitors

Compass Therapeutics logo
$2.76 +0.12 (+4.34%)
As of 02:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CMPX vs. ETNB, ANIP, MESO, EWTX, JANX, TVTX, CVAC, CALT, GPCR, and AUPH

Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry.

Compass Therapeutics vs. Its Competitors

89BIO (NASDAQ:ETNB) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

89BIO currently has a consensus target price of $26.43, suggesting a potential upside of 149.56%. Compass Therapeutics has a consensus target price of $12.67, suggesting a potential upside of 358.11%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than 89BIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
89BIO
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00
Compass Therapeutics
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.10

Compass Therapeutics' return on equity of -42.47% beat 89BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
89BION/A -81.44% -70.17%
Compass Therapeutics N/A -42.47%-38.31%

Compass Therapeutics has higher revenue and earnings than 89BIO. Compass Therapeutics is trading at a lower price-to-earnings ratio than 89BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
89BION/AN/A-$367.08M-$3.38-3.13
Compass Therapeutics$850K449.82-$49.38M-$0.41-6.74

68.4% of Compass Therapeutics shares are held by institutional investors. 2.8% of 89BIO shares are held by company insiders. Comparatively, 29.8% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Compass Therapeutics' average media sentiment score of 0.86 beat 89BIO's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
89BIO Neutral
Compass Therapeutics Positive

89BIO has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.

Summary

Compass Therapeutics beats 89BIO on 12 of the 14 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMPX vs. The Competition

MetricCompass TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$382.34M$2.92B$5.54B$8.99B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-6.7421.0627.5520.17
Price / Sales449.82288.78432.66125.29
Price / CashN/A41.1936.8257.86
Price / Book3.047.808.105.60
Net Income-$49.38M-$54.95M$3.17B$248.58M
7 Day Performance5.53%5.88%4.21%5.33%
1 Month Performance7.59%5.30%3.85%7.26%
1 Year Performance219.28%7.96%34.49%21.87%

Compass Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMPX
Compass Therapeutics
3.0829 of 5 stars
$2.77
+4.3%
$12.67
+358.1%
+208.1%$382.34M$850K-6.7420
ETNB
89BIO
1.5662 of 5 stars
$9.82
-0.4%
$26.43
+169.1%
+25.9%$1.43BN/A-2.9140
ANIP
ANI Pharmaceuticals
3.4101 of 5 stars
$65.25
-0.4%
$80.13
+22.8%
+4.3%$1.41B$614.38M-51.38600
MESO
Mesoblast
1.9853 of 5 stars
$10.89
-0.3%
$18.00
+65.3%
+35.2%$1.39B$5.67M0.0080
EWTX
Edgewise Therapeutics
2.6375 of 5 stars
$13.11
-0.5%
$40.00
+205.1%
-37.8%$1.38BN/A-8.4660
JANX
Janux Therapeutics
2.059 of 5 stars
$23.10
-0.2%
$95.25
+312.3%
-38.0%$1.37B$10.59M-16.9930
TVTX
Travere Therapeutics
3.3303 of 5 stars
$14.80
+0.2%
$32.14
+117.2%
+75.5%$1.31B$233.18M-5.27460Gap Up
CVAC
CureVac
4.5018 of 5 stars
$5.43
+0.9%
$6.83
+25.8%
+73.2%$1.22B$579.18M5.90880
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
GPCR
Structure Therapeutics
2.6816 of 5 stars
$20.74
-1.6%
$76.17
+267.2%
-49.7%$1.19BN/A-23.84136
AUPH
Aurinia Pharmaceuticals
2.7385 of 5 stars
$8.47
-2.0%
$11.50
+35.8%
+34.8%$1.14B$235.13M30.25300

Related Companies and Tools


This page (NASDAQ:CMPX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners